Additionally, BAFF-blocking therapies, such as Belimumab (Benlysta), which is FDA-approved in treating SLE, could be contemplated to try to control BAFF levels in order to lower the inflammatory burden and restore B-cell immune competence. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.